Overview

Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.

Status:
Not yet recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis

Phase:

Phase 4

Details

Lead Sponsor:

Juan A. Arnaiz

Treatments:

Octreotide
Terlipressin